Literature DB >> 30868235

Risk factors for failure of vitrectomy cell block technique in cytological diagnosis of vitreoretinal lymphoma.

Takako Ito1, Atsunobu Takeda2,3, Kohta Fujiwara1,4, Eiichi Hasegawa1, Shintaro Nakao1, Yoshihiro Ohishi5, Yoshinao Oda5, Hiroshi Yoshikawa1, Koh-Hei Sonoda1.   

Abstract

PURPOSE: To determine the factors that may affect the accuracy of vitrectomy cell block technique in detecting atypical lymphoid cells in patients with vitreoretinal lymphoma (VRL).
METHODS: We retrospectively reviewed 43 eyes in 39 patients who underwent vitrectomy for definitive histological diagnosis of VRL with vitrectomy cell block technique and/or smear preparation at Kyushu University Hospital from January 2001 to March 2016. The association of detection of atypical lymphoid cells using vitrectomy cell block technique with the following factors was assessed using logistic regression analysis: age at diagnosis, sex, presence or absence of concurrent cataract surgery with vitrectomy, clinical grading of vitreous haze, presence or absence of subretinal tumor infiltration, interval between initial symptoms and vitrectomy, and presence or absence of systemic corticosteroid therapy before vitrectomy.
RESULTS: Atypical lymphoid cells were more significantly detected using vitrectomy cell block technique compared to that using smear preparation (p = 0.018). After adjusting for age and sex, concurrent cataract surgery (odds ratio [OR], 10.41; 95% confidence interval [CI], 1.42-76.41) and subretinal tumor infiltration (OR, 5.06; 95% CI, 1.06-24.32) were significantly associated with failure of histological analysis with vitrectomy cell blocks. In multivariable logistic regression analysis, similar results were obtained, although subretinal tumor infiltration was only marginally associated with the detective capability of the technique.
CONCLUSION: Vitrectomy cell block technique significantly improved the definitive diagnosis of VRL. Concurrent cataract surgery with vitrectomy and subretinal tumor infiltration were risk factors for failure in vitrectomy cell blocks.

Entities:  

Keywords:  Concurrent cataract surgery; Single-center study; Subretinal tumor infiltration; Vitrectomy cell block technique; Vitreoretinal lymphoma

Mesh:

Year:  2019        PMID: 30868235     DOI: 10.1007/s00417-019-04266-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  41 in total

1.  Immunocytochemical diagnosis as inflammation by vitrectomy cell blocks in patients with vitreous opacity.

Authors:  Toshihiko Matsuo; Kouichi Ichimura
Journal:  Ophthalmology       Date:  2012-01-26       Impact factor: 12.079

2.  Intraocular lymphoma: more questions than answers.

Authors:  Denis Wakefield; Manfred Zierhut
Journal:  Ocul Immunol Inflamm       Date:  2009 Jan-Feb       Impact factor: 3.070

Review 3.  Pathophysiology of retinal lymphoma.

Authors:  Sarah E Coupland; Chi Chao Chan; Justine Smith
Journal:  Ocul Immunol Inflamm       Date:  2009 Jul-Aug       Impact factor: 3.070

4.  PREVALENCE OF MYD88 L265P MUTATION IN HISTOLOGICALLY PROVEN, DIFFUSE LARGE B-CELL VITREORETINAL LYMPHOMA.

Authors:  Harish Raja; Diva R Salomão; David S Viswanatha; Jose S Pulido
Journal:  Retina       Date:  2016-03       Impact factor: 4.256

5.  A review of 50 consecutive cytology cell block preparations in a large general hospital.

Authors:  F Mayall; B Chang; A Darlington
Journal:  J Clin Pathol       Date:  1997-12       Impact factor: 3.411

Review 6.  Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features.

Authors:  Sarah E Coupland; Heinrich Heimann; Nikolaos E Bechrakis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-10-29       Impact factor: 3.117

7.  Diagnostic testing of vitrectomy specimens.

Authors:  Janet L Davis; Daniel M Miller; Phillip Ruiz
Journal:  Am J Ophthalmol       Date:  2005-11       Impact factor: 5.258

8.  Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown.

Authors:  Taiji Sakamoto; Miho Miyazaki; Toshio Hisatomi; Takao Nakamura; Akifumi Ueno; Keiko Itaya; Tatsuro Ishibashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-03-15       Impact factor: 3.117

Review 9.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

10.  Cataract formation following vitreoretinal procedures.

Authors:  Hao Feng; Ron A Adelman
Journal:  Clin Ophthalmol       Date:  2014-09-23
View more
  5 in total

Review 1.  New Insights Into Immunological Therapy for Retinal Disorders.

Authors:  Atsunobu Takeda; Ryoji Yanai; Yusuke Murakami; Mitsuru Arima; Koh-Hei Sonoda
Journal:  Front Immunol       Date:  2020-07-03       Impact factor: 7.561

2.  Diagnosing Vitreoretinal Lymphomas-An Analysis of the Sensitivity of Existing Tools.

Authors:  Anahita Sehgal; Jose S Pulido; Arman Mashayekhi; Tatyana Milman; Gabor Gy Deák
Journal:  Cancers (Basel)       Date:  2022-01-25       Impact factor: 6.639

3.  Diagnostic Accuracy of Cell Block Preparations and Clinical Features Affecting It in Vitreoretinal Lymphoma.

Authors:  Satoru Kase; Kenichi Namba; Daiju Iwata; Kazuomi Mizuuchi; Kayo Suzuki; Takako Ito; Keitaro Hase; Nobuyoshi Kitaichi; Susumu Ishida
Journal:  J Clin Med       Date:  2022-03-03       Impact factor: 4.241

4.  Optical Coherence Tomography Benefits the Diagnosis and Follow-Up of Primary Central Nervous System Lymphoma with Intraocular Involvement.

Authors:  Xianjin Zhou; Sha Tian; Xian Zhou; Huimin Shi; Yi Li; Jianjiang Xiao; Kun Chen; Bobin Chen; Gezhi Xu; Qingping Wang
Journal:  Cancer Manag Res       Date:  2022-03-05       Impact factor: 3.989

5.  Vitreous levels of interleukin-35 as a prognostic factor in B-cell vitreoretinal lymphoma.

Authors:  Atsunobu Takeda; Eiichi Hasegawa; Shintaro Nakao; Keijiro Ishikawa; Yusuke Murakami; Toshio Hisatomi; Mitsuru Arima; Nobuyo Yawata; Yoshinao Oda; Kazuhiro Kimura; Hiroshi Yoshikawa; Koh-Hei Sonoda
Journal:  Sci Rep       Date:  2020-09-24       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.